Today marks World Earth Day, with the theme “Planet vs. Plastics”. At Helsinn we are committed to decreasing plastic use, and launched our Plasticless initiative in 2019, with a particular focus on the reduction of plastic use in our canteen.

Are you interested in learning more about ADCs and cancer supportive care? Join the webinar hosted by MASCC on “Antibody-Drug Conjugates (ADCs)-Induced Nausea and Vomiting and Long-Delayed CINV: New Unmet Medical Needs”. mascc.org/mascc-webinar-…

May marks #SkinCancerAwarenessMonth. Helsinn is particularly focused on raising awareness about mycosis fungoides, a form of cutaneous T-cell lymphoma (MF-CTCL), presents a diagnostic challenge because it shares common features with non-malignant skin conditions.

Don’t forget the webinar organized by MASCC on the topic of “Antibody-Drug Conjugates (ADCs)-Induced Nausea and Vomiting and Long-Delayed CINV: New Unmet Medical Needs”. Friday, May 10, 2024 Click here to sign up: mascc.org/mascc-webinar-…

We are excited to be attending BIO International Conference in San Diego, California from 3-6 June 2024, where we hope to reconnect with leaders across the biotech and pharmaceutical industry. Find out more about the conference here: convention.bio.org #BIO24

At #ESMOBreast24, a poster presents a survey of healthcare providers’ experience with antibody drug conjugates (ADCs). Findings reveal common long-delayed nausea and vomiting (N&V) and emphasize the need for increased awareness of ADC-induced N&V.

Breast cancer patients are at higher risk of developing nausea and vomiting as a consequence of the treatment choices. An optimal management of nausea and vomiting is mandatory. #ESMOBreast24 #supportivecare

New Antibody–drug conjugates (ADCs) are an important therapeutic breakthrough in oncology, particularly in the field of breast cancers; with gastrointestinal toxicity as key dose-limiting toxicity. #ESMOBreast24 #supportivecare

Meet our BD Lead, Luis Vieira at #BIO24. Our current business development strategy is focused on in-licensing or commercial partnerships of late-stage assets in Supportive Care, niche Oncology and specialized Dermatology for our US affiliate and/or worldwide rights.

The ASCO Annual Meeting starts tomorrow! The Helsinn team on the ground in Chicago is looking forward to welcoming you at #26015 booth in the exhibition hall. #ASCO24 #supportivecare

Attending the ASCO Annual Meeting this weekend? If you would like to meet the Helsinn team and find more about our commitment to #supportivecare, visit us at booth #26015. #ASCO24 #oncology

Are you attending #BIO24? Don’t miss the opportunity to learn more about Helsinn and what makes us a partner of choice. Please reach out if you would like to hear more about Helsinn’s offering or visit: helsinn.com #partnering

Celebrate #WorldEnvironmentDay with us! At Helsinn, we're committed to a sustainable future: · Carbon Neutral since 2021✅ · Using renewable electricity ☀️ · Investing in solar panels & electric vehicle charging stations · We're on a path to becoming Net-Zero!

We are pleased to announce the renewal of our commercial agreement with Chugai Pharma Europe to continue supporting patients with chemotherapy-induced nausea and vomiting (CINV) in the UK and Ireland. Dr. Melanie Rolli, Helsinn Group CEO, commented:

Today marks the start of WellBeing Week. At Helsinn Birex Pharmaceuticals we particularly care about our employees’ health. Each year we offer a Wellbeing plan that includes a series of regular activities for the welfare of body and mind. #wellbeing

Helsinn highlights new antiemetic guidelines from MASCC/ESMO recommending a triple NK1 RA-containing combo for high-end moderate emetogenic situations (eg, carboplatin (AUC ≥ 5), women < 50 receiving oxaliplatin, patients on ADCs like T-DXd and sacituzumab-govitecan).

Today, we have the opportunity to be on the ground and connect with the healthcare community at the MASCC Annual Meeting in Paris. We have the chance to explore the latest advances in #supportivecare to reinforce our commitment to improving patients' quality of life. #MASCC24

We are pleased to announce that AKYNZEO® injection (fosnetupitant/palonosetron) is now available in the US in a ready-to-use vial. Dr. Melanie Rolli expresses her insights on this significant milestone:

New findings on some antibody-drug conjugates (ADCs) suggest that nausea and vomiting can last more than 5 days (long-delayed CINV), making use of recommended antiemetics crucial for optimizing patient outcomes given the extended treatment duration of ADCs. #seeCINVbetter

The origins of the #company date back to 1976. Since then, a story of international growth, global presence and strong partnerships has been nurtured, all focused on improving patients’ quality of life. Learn more about us on our renewed corporate website: helsinn.com/about-us/